"The voice for cancer physicians and their patients in Massachusetts."

FDA approves atezolizumab (Tecentriq) for BRAF V600 unresectable or metastatic melanoma

03 Aug 2020 7:18 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with cobimetinib and vemurafenib for patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software